HMN-214
CAS: 173529-46-9
Ref. 3D-FH170580
| 1mg | Descatalogado | ||
| 2mg | Descatalogado | ||
| 5mg | Descatalogado | ||
| 10mg | Descatalogado | ||
| 25mg | Descatalogado |
Información del producto
Nombre:
HMN-214
Sinónimos:
- (E)-4-[2-[2-[N-Acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide
- Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-
- Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-, (E)-
- Hmn-214
- Ivx 214
- N-[(4-Methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]acetamide
Descripción:
HMN-214 is a novel oral prodrug that is being developed as a single agent therapy for the treatment of cancer. HMN-214 is a prodrug of the natural product dihydromyricetin, which inhibits mitochondrial complex I and II. HMN-214 has shown potent antitumor activity in tumor xenografts and demonstrated safety profile in vivo. The drug also induces cancer cell death via a mechanism that involves inhibition of kinase domain phosphorylation, leading to apoptosis induction. HMN-214 has been tested in vitro and in vivo for pharmacokinetics and gene expression profiling with promising results.
Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Biosynth
Almacenamiento de larga duración:
Notas:
Propiedades químicas
Peso molecular:
424.47 g/mol
Fórmula:
C22H20N2O5S
Pureza:
Min. 95%
MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:
